1. XMRV status determined by the WPI since the submission to Science. ID#XMRV status Clonal TCR  Lymphoma/cancer 1103positive MCL 1109positivenegativeThymoma 1118positivenegativemyelodysplasia 1125positivePositive + IGHMCL 1186positive Lymphoma 1199positive Previous Lymphoma 1150positive Lymphoma 1320Not tested Thymoma 1321Not tested MCL 1174positive Thymoma 1205positiveNot testedlymphoma 1172positive MCL 1135positive suspicious 1204positivePositive + IGHsuspicious 1113positive CLL 1322Not tested MCL 1181positiveNot testedCLL 1188positive CLL 1189positive MCL 1190positive suspicious XMRV status determined by the WPI since the submission to Science. WPI Repository CFS Subjects with Cancer

2. 1988- seen at NIH for CFS 1998- Splenectomy to decrease aggressiveness. 2000- seen at NIH for mantle cell lymphoma. Given Rituxan and Velcade 2004- BMT with adult stem cells 2008- Blast crisis MCL…. death 1988---Seen at NIH for CFS 1988---Seen at NIH for CFS 1998---Splenectomy to decrease aggressiveness. 1998---Splenectomy to decrease aggressiveness. 2000---Seen at NIH for mantle cell lymphoma. Given Rituxan 2000---Seen at NIH for mantle cell lymphoma. Given Rituxan and Velcade and Velcade 2004---BMT with adult stem cells 2004---BMT with adult stem cells 2008---Blast crisis MCL … death 2008---Blast crisis MCL … death MCL cell line developed 2008 WPI-1125 CFS Diagnosis One Decade Prior to MCL

3. Relationship between RNaseL variant genotype and XMRV expression in CFS patients Neither XMRV infection nor a diagnosis of CFS correlate to RNase L genetic variation R462Q

4. Dysfunction of Natural Killer Activity in a Family with Chronic Fatigue Syndrome

5. Relative time-scale of the virological and immunological events during XMRV infection CFS develops Env antigen Hypothesis of XMRV disease progression: NK dysregulation